Business Wire
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
📈
AI Sentiment
Highly Positive
8/10
- Home
- DMAC
as of 12-18-2025 3:38pm EST
$8.28
+$0.07
+0.80%
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Chart Type:
Time Range:
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 457.2M | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 530.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.19 - $10.42 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered DMAC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 65.31%
65.31%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of DiaMedica Therapeutics Inc. (DMAC)
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 25, 2025
Avg Cost/Share
$8.57
Shares
73,099
Total Value
$626,816.62
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 24, 2025
Avg Cost/Share
$7.89
Shares
40,253
Total Value
$317,720.95
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 21, 2025
Avg Cost/Share
$7.41
Shares
208,872
Total Value
$1,547,574.42
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 20, 2025
Avg Cost/Share
$7.41
Shares
128,426
Total Value
$951,212.85
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 19, 2025
Avg Cost/Share
$7.21
Shares
240,352
Total Value
$1,732,361.08
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 18, 2025
Avg Cost/Share
$6.75
Shares
182,882
Total Value
$1,234,618.09
Owned After
8,825,742
SEC Form 4
STAHLBERG JAN
Buy
10% Owner
DMAC Nov 17, 2025
Avg Cost/Share
$6.52
Shares
187,393
Total Value
$1,221,165.22
Owned After
8,825,742
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | DMAC | 10% Owner | Nov 25, 2025 | Buy | $8.57 | 73,099 | $626,816.62 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 24, 2025 | Buy | $7.89 | 40,253 | $317,720.95 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 21, 2025 | Buy | $7.41 | 208,872 | $1,547,574.42 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 20, 2025 | Buy | $7.41 | 128,426 | $951,212.85 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 19, 2025 | Buy | $7.21 | 240,352 | $1,732,361.08 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 18, 2025 | Buy | $6.75 | 182,882 | $1,234,618.09 | 8,825,742 | |
| STAHLBERG JAN | DMAC | 10% Owner | Nov 17, 2025 | Buy | $6.52 | 187,393 | $1,221,165.22 | 8,825,742 |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
Compare DMAC vs Leading Stocks
See how DMAC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.